Skip to content

Investor Relations / Publications / Publications Search

Publications Search

Hilleman DE, Wiggins BS, Bottorff MB. A Response to: Letter to the Editor Regarding “Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: a Narrative Review.” Adv Ther. 2020; epub ahead of print.

https://link.springer.com/article/10.1007/s12325-020-01420-z
Majithia A, Bhatt DL, Friedman AN, et al. Benefits of icosapent ethyl across a range of baseline renal function in patients with established cardiovascular disease or diabetes: results of REDUCE-IT RENAL [abstract FR-OR18]. J Am Soc Nephrol. 2020;31(suppl):21. https://www.asn-online.org/education/kidneyweek/archives/KW20Abstracts.pdf
European Association for the Study of Diabetes
Bhatt DL, Brinton E, Miller M, et al. Substantial cardiovascular benefit from icosapent ethyl in patients with diabetes: REDUCE-IT DIABETES [abstract 627]. Presented at the European Association for the Study of Diabetes meeting, September 21-25, 2020 (virtual). Diabetologia. 2020;63(1 suppl):303. https://upload.easd.org/download/EASD2020/Abstract%20Volume%2056th%20EASD%20Annual%20Meeting.pdf
REDUCE-IT: total ischemic events reduced across the full range of baseline LDL cholesterol and other key subgroups.
European Society of Cardiology – Freely accessible
Bhatt DL, Miller M, Steg PG, et al. REDUCE-IT: total ischemic events reduced across the full range of baseline LDL cholesterol and other key subgroups. Presented at the European Society of Cardiology meeting, August 29-September 2, 2020 (virtual).
REDUCE-IT: Accumulation of data across prespecified interim analyses to final results.
Olshansky B, Bhatt DL, Miller M, et al. REDUCE-IT: Accumulation of data across prespecified interim analyses to final results. Presented at the European Society of Cardiology meeting, August 29-September 2, 2020 (virtual).
Treatment with icosapent ethyl to reduce ischemic events in patients with prior percutaneous coronary intervention - insights from REDUCE-IT PCI.
Transcatheter Cardiovascular Therapeutics Scientific Symposium
Peterson BE, Bhatt DL, Steg PG, et al. Treatment with icosapent ethyl to reduce ischemic events in patients with prior percutaneous coronary intervention - insights from REDUCE-IT PCI. Presented at the Transcatheter Cardiovascular Therapeutics Scientific Symposium, October 14-18, 2020 (virtual).
copyright
© 2021, Amarin Corporation
Privacy policy  |  Disclaimer
Dublin Office
Spaces South Docklands
Block C
77 Sir John Rogerson's Quay
Dublin 2, D02 VK60
Investor Relations
AMARIN CORPORATION PLC C/O AMARIN PHARMA, INC.
440 ROUTE 22
BRIDGEWATER, NJ 08807
investor.relations@amarincorp.com
Fax:
+1 908 719 3012

Amarin Corporation